293 related articles for article (PubMed ID: 17441749)
1. Attachment of LcrV from Yersinia pestis at dual binding sites to human TLR-2 and human IFN-gamma receptor.
Abramov VM; Khlebnikov VS; Vasiliev AM; Kosarev IV; Vasilenko RN; Kulikova NL; Khodyakova AV; Evstigneev VI; Uversky VN; Motin VL; Smirnov GB; Brubaker RR
J Proteome Res; 2007 Jun; 6(6):2222-31. PubMed ID: 17441749
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
[TBL] [Abstract][Full Text] [Related]
3. Binding of LcrV protein from Yersinia pestis to human T-cells induces apoptosis, which is completely blocked by specific antibodies.
Abramov VM; Kosarev IV; Motin VL; Khlebnikov VS; Vasilenko RN; Sakulin VK; Machulin AV; Uversky VN; Karlyshev AV
Int J Biol Macromol; 2019 Feb; 122():1062-1070. PubMed ID: 30218736
[TBL] [Abstract][Full Text] [Related]
4. A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2-mediated IL-10 induction and mouse virulence.
Sing A; Reithmeier-Rost D; Granfors K; Hill J; Roggenkamp A; Heesemann J
Proc Natl Acad Sci U S A; 2005 Nov; 102(44):16049-54. PubMed ID: 16239347
[TBL] [Abstract][Full Text] [Related]
5. The weak interaction of LcrV and TLR2 does not contribute to the virulence of Yersinia pestis.
Reithmeier-Rost D; Hill J; Elvin SJ; Williamson D; Dittmann S; Schmid A; Wilharm G; Sing A
Microbes Infect; 2007 Jul; 9(8):997-1002. PubMed ID: 17556003
[TBL] [Abstract][Full Text] [Related]
6. Yersinia V antigen induces both TLR homo- and heterotolerance in an IL-10-involving manner.
Reithmeier-Rost D; Bierschenk S; Filippova N; Schröder-Braunstein J; Sing A
Cell Immunol; 2004; 231(1-2):63-74. PubMed ID: 15919371
[TBL] [Abstract][Full Text] [Related]
7. N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection.
Hill J; Leary S; Smither S; Best A; Pettersson J; Forsberg A; Lingard B; Lipka A; Brown KA; Williamson ED; Titball RW
Vaccine; 2009 Nov; 27(50):7073-9. PubMed ID: 19786138
[TBL] [Abstract][Full Text] [Related]
8. Contribution of toll-like receptors 2 and 4 in an oral Yersinia enterocolitica mouse infection model.
Sing A; Tvardovskaia N; Rost D; Kirschning CJ; Wagner H; Heesemann J
Int J Med Microbiol; 2003 Nov; 293(5):341-8. PubMed ID: 14695062
[TBL] [Abstract][Full Text] [Related]
9. Amino acid substitutions in LcrV at putative sites of interaction with Toll-like receptor 2 do not affect the virulence of Yersinia pestis.
Sun W; Curtiss R
Microb Pathog; 2012; 53(5-6):198-206. PubMed ID: 22841961
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.
Miller NC; Quenee LE; Elli D; Ciletti NA; Schneewind O
Infect Immun; 2012 Apr; 80(4):1572-82. PubMed ID: 22252870
[TBL] [Abstract][Full Text] [Related]
11. Interactions between Yersinia pestis V-antigen (LcrV) and human Toll-like receptor 2 (TLR2) in a modelled protein complex and potential mechanistic insights.
Wei T; Gong J; Qu G; Wang M; Xu H
BMC Immunol; 2019 Dec; 20(1):48. PubMed ID: 31842739
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the role of LcrV-Toll-like receptor 2-mediated immunomodulation in the virulence of Yersinia pestis.
Pouliot K; Pan N; Wang S; Lu S; Lien E; Goguen JD
Infect Immun; 2007 Jul; 75(7):3571-80. PubMed ID: 17438030
[TBL] [Abstract][Full Text] [Related]
13. Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis.
Khan AA; Babu JP; Gupta G; Rao DN
Vaccine; 2008 Jan; 26(3):316-32. PubMed ID: 18096277
[TBL] [Abstract][Full Text] [Related]
14. Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages.
Noel BL; Lilo S; Capurso D; Hill J; Bliska JB
Clin Vaccine Immunol; 2009 Oct; 16(10):1457-66. PubMed ID: 19710295
[TBL] [Abstract][Full Text] [Related]
15. Effect of rLcrV and rYopB from Yersinia pestis on murine peritoneal macrophages in vitro.
Sharma RK; Sodhi A; Batra HV; Tuteja U
Immunol Lett; 2004 May; 93(2-3):179-87. PubMed ID: 15158615
[TBL] [Abstract][Full Text] [Related]
16. Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates.
Tunheim G; Thompson KM; Fredriksen AB; Espevik T; Schjetne KW; Bogen B
Vaccine; 2007 Jun; 25(24):4723-34. PubMed ID: 17499405
[TBL] [Abstract][Full Text] [Related]
17. Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis.
Philipovskiy AV; Cowan C; Wulff-Strobel CR; Burnett SH; Kerschen EJ; Cohen DA; Kaplan AM; Straley SC
Infect Immun; 2005 Mar; 73(3):1532-42. PubMed ID: 15731051
[TBL] [Abstract][Full Text] [Related]
18. Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague.
Leary SE; Griffin KF; Galyov EE; Hewer J; Williamson ED; Holmström A; Forsberg A; Titball RW
Microb Pathog; 1999 Mar; 26(3):159-69. PubMed ID: 10089156
[TBL] [Abstract][Full Text] [Related]
19. The structure of Yersinia pestis V-antigen, an essential virulence factor and mediator of immunity against plague.
Derewenda U; Mateja A; Devedjiev Y; Routzahn KM; Evdokimov AG; Derewenda ZS; Waugh DS
Structure; 2004 Feb; 12(2):301-6. PubMed ID: 14962390
[TBL] [Abstract][Full Text] [Related]
20. Direct neutralization of type III effector translocation by the variable region of a monoclonal antibody to Yersinia pestis LcrV.
Ivanov MI; Hill J; Bliska JB
Clin Vaccine Immunol; 2014 May; 21(5):667-73. PubMed ID: 24599533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
